### **CONSOLIDATED FINANCIAL STATEMENTS**

Year Ended December 31, 2015

### **CONSOLIDATED FINANCIAL STATEMENTS**

Year Ended December 31, 2015

### **CONTENTS**

**Pages** 

INDEPENDENT ACCOUNTANTS' REVIEW REPORT	1
CONSOLIDATED FINANCIAL STATEMENTS	
Consolidated Statement of Financial Position	2
Consolidated Statement of Activities and Changes in Net Assets	3
Consolidated Statement of Cash Flows	4
Notes to Consolidated Financial Statements	5 - 16
SUPPLEMENTAL INFORMATION	
Independent Accountants' Review Report on Supplemental Information	17
Schedule of Departmental Assets, Liabilities and Net Assets	18
Schedule of Departmental Revenues and Expenses	19



#### INDEPENDENT ACCOUNTANTS' REVIEW REPORT

To the Board of Directors of

### ALCOR LIFE EXTENSION FOUNDATION, INC. AND AFFILIATES

We have reviewed the accompanying consolidated financial statements of *Alcor Life Extension Foundation, Inc. and Affiliates* (the "Foundation"), which comprise the consolidated statement of financial position as of December 31, 2015, the related consolidated statements of activities and changes in net assets and cash flows for the year then ended, and the related notes to the consolidated financial statements. A review includes primarily applying analytical procedures to management's financial data and making inquiries of organization management. A review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the consolidated financial statements as a whole. Accordingly, we do not express such an opinion.

#### Management's Responsibility for the Consolidated Financial Statements

Mayer Hoffman McCann P.C.

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement whether due to fraud or error.

#### Accountants' Responsibility

Our responsibility is to conduct the review engagement in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require us to perform procedures to obtain limited assurance as a basis for reporting whether we are aware of any material modifications that should be made to the consolidated financial statements for them to be in accordance with accounting principles generally accepted in the United States of America. We believe that the results of our procedures provide a reasonable basis for our conclusion.

#### **Accountants' Conclusion**

Based on our review, we are not aware of any material modifications that should be made to the accompanying consolidated financial statements in order for them to be in accordance with accounting principles generally accepted in the United States of America.

May 17, 2018



### **CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

December 31, 2015 (with comparative totals at December 31, 2014)

_	_	_		
Δ	S	S	FΤ	

		2015		2014
CURRENT ASSETS Cash and cash equivalents Accounts receivable, net Other current assets TOTAL CURRENT ASSETS	\$	1,392,475 74,654 194,956 1,662,085	\$	1,439,426 96,722 215,017 1,751,165
RESTRICTED CASH		514,979		430,769
PROPERTY AND EQUIPMENT, net		712,675		677,193
INVESTMENTS		14,950,474		14,849,399
BENEFICIAL INTEREST IN PERPETUAL TRUST		3,509,058		3,320,068
PREPAID CRYOPRESERVATION AND STANDBY	_	8,484,230	_	6,584,612
TOTAL ASSETS	\$	29,833,501	\$	27,613,206
<u>LIABILITIES AND NET ASSETS</u>				
CURRENT LIABILITIES Accounts payable Accrued expenses	\$	154,825 50,629	\$	67,634 44,077
TOTAL CURRENT LIABILITIES		205,454		111,711
DEFERRED CRYOPRESERVATION AND STANDBY REVENUE		8,484,230		6,584,612
DEFERRED COMPREHENSIVE MEMBER STANDBY REVENUE		527,520		385,441
DEFERRED REVENUE		142,119		55,364
DEFERRED PATIENT CARE RESERVE	_	8,135,000	_	7,750,000
TOTAL LIABILITIES	_	17,494,323		14,887,128
NET ASSETS Unrestricted				
Controlling interest Noncontrolling interest		8,789,579 40,541		9,368,851 37,159
Total unrestricted Temporarily restricted	_	8,830,120		9,406,010
Permanently restricted		3,509,058		3,320,068
TOTAL NET ASSETS	_	12,339,178		12,726,078
TOTAL LIABILITIES AND NET ASSETS	\$	29,833,501	\$	27,613,206

### CONSOLIDATED STATEMENT ACTIVITIES AND CHANGES IN NET ASSETS

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

			-	Temporarily	Pe	rmanently	Tota		als	
	Ur	nrestricted		Restricted		estricted		2015		2014
REVENUE AND SUPPORT										
Membership dues	\$	434,862	\$	-	\$	-	\$	434,862	\$	478,568
Bequests		279,488		-		-		279,488		120,924
Contributions		346,467		-		-		346,467		281,723
Interest and distribution income		284,623		-		-		284,623		213,285
Realized and unrealized gains (losses) on investments		(641,938)		-		-		(641,938)		670,379
Cryopreservation and standby		776,136		-		-		776,136		675,330
Rental income		26,031		-		-		26,031		49,205
Change in value of beneficial interest in perpetual trust		-		-		188,990		188,990		197,538
Other		48,554		-				48,554		67,835
Total revenue and support before net assets										
released from restrictions		1,554,223		-		188,990		1,743,213		2,754,787
Net assets released from restrictions		· · · · -		-		· -		· · · · -		· · · -
			_							
TOTAL REVENUE AND SUPPORT		1,554,223	-	-		188,990	_	1,743,213	_	2,754,787
EXPENSES										
Payroll and benefits		654,061		_		_		654,061		597,770
Professional fees		127,224		_		_		127,224		92,495
Marketing		22,849		_		_		22,849		6,728
Depreciation		103,961						103,961		102,519
Bad debts				-		-				
		93,812		-		-		93,812		13,046
Office supplies		60,716		-		-		60,716		55,943
Cryopreservation		359,141		-		-		359,141		341,549
Liquid nitrogen		29,779		-		-		29,779		30,070
Utilities		49,682		-		-		49,682		49,706
Insurance		60,613		-		-		60,613		52,143
Taxes, licenses, and permits		43,671		-		-		43,671		19,808
Readiness		87,092		-		-		87,092		52,525
Royalty		20,268		-		-		20,268		19,678
Contract services		15,033		-		-		15,033		16,424
Repairs and maintenance		17,200		-		-		17,200		20,230
Bank charges		39,873		-		-		39,873		24,488
Travel		6,277		-		-		6,277		8,436
Research and development		60,454		-		-		60,454		55,059
Management fee		´-		-		-		´-		7,213
Lease expense		3,594		_		_		3,594		3,516
Public education		274,813		_		_		274,813		120,095
Miscellaneous		,		_		_		,		620
TOTAL EXPENSES		2,130,113	-		_	_	_	2,130,113		1,690,061
TOTAL EAF LINGES		2,130,113		_		-		2,130,113		1,090,001
LOSS ON PATIENT CARE RESERVE			_	-		-		-	_	382,500
CHANGE IN NET ASSETS		(575,890)		-		188,990		(386,900)		682,226
NET ASSETS, BEGINNING OF YEAR	_	9,406,010	-	-	_	3,320,068	_	12,726,078	_	12,043,852
NET ASSETS, END OF YEAR	\$	8,830,120	\$	<del>-</del>	\$	3,509,058	\$	12,339,178	\$	12,726,078
CHANGE IN NET ASSETS ATTRIBUTABLE TO										
NONCONTROLLING INTEREST	\$	3,382	\$	-	\$	-	\$	3,382	\$	9,140
CHANGE IN NET ASSETS ATTRIBUTABLE TO	*	-,	•				,	-,	,	-,
CONTROLLING INTEREST		(579,272)	_			188,990	_	(390,282)	_	673,086
CHANGE IN NET ASSETS	\$	(575,890)	\$	; -	\$	188,990	\$	(386,900)	\$	682,226
	Ψ	(3. 3,000)	*		<u>~</u>	. 55,000	<u>*</u>	(000,000)	<u>*</u>	552,225

### **CONSOLIDATED STATEMENT OF CASH FLOWS**

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

	 2015		2014
CASH FLOWS FROM OPERATING ACTIVITIES			
Change in net assets attributable to controlling interest	\$ (390,282)	\$	673,086
Adjustments to reconcile the change in net assets attributable			
to controlling interest to net cash provided by operating activities:			
Change in value of a beneficial interest in perpetual trust	(188,990)		(197,538)
Change in net assets attributable to noncontrolling interest	3,382		9,140
Provision for bad debts	93,812		13,046
Depreciation	103,961		102,519
Realized and unrealized losses (gains) on investments	641,938		(670,379)
Loss on patient care reserve	-		382,500
Changes in operating assets and liabilities:			
Decrease (increase) in:			
Accounts receivable	(71,744)		124,430
Other current assets	20,061		(13,023)
Prepaid cryopreservation and standby	(1,899,618)		(1,142,376)
Increase (decrease) in:			
Accounts payable	87,191		38,863
Accrued expenses	6,552		(2,337)
Deferred cryopreservation and comprehensive member revenues	2,041,697		1,200,730
Deferred revenue	86,755		22,700
Deferred patient care reserve	 385,000		612,500
Net cash provided by operating activities	 919,715		1,153,861
CASH FLOWS FROM INVESTING ACTIVITIES			
Change in restricted cash	(84,210)		112,174
Purchase of property and equipment	(139,443)		(142,096)
Purchases of investments	(827,438)		(891,732)
Proceeds from sale of investments	84,425		278,098
		_	
Net cash used in investing activities	 (966,666)		(643,556)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(46,951)		510,305
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	 1,439,426		929,121
CASH AND CASH EQUIVALENTS, END OF YEAR	\$ 1,392,475	\$	1,439,426

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

#### (1) Nature of operations and summary of significant accounting policies

Nature of operations – *Alcor Life Extension Foundation, Inc.* ("Alcor") is a California non-profit organization formed under Section 501(c)(3) of the Internal Revenue Code. Alcor conducts its primary operations in Scottsdale, Arizona. Alcor is funded primarily through contributions and membership dues from its members, and rental income. Alcor's primary exempt purpose is research and education in the science of cryonic storage and cryopreservation. Members guarantee a certain level of funding which will be paid to Alcor upon the legal death of the member to support Comprehensive Member Standby ("CMS"), cryopreservation, long-term care, and, if it becomes possible, resuscitation of the member.

The significant accounting policies of Alcor are as follows:

**Principles of consolidation** – The consolidated financial statements include all accounts of Alcor Life Extension Foundation, Inc. and its affiliates, Alcor Endowment Trust Supporting Organization ("Endowment Trust"), the Alcor Patient Care Trust (the "Trust") and Cryonics Property, LLC (the "LLC"). The Trust had an ownership interest of 84.0580% in the LLC at December 31, 2015 and 2014. Alcor is the beneficiary of the Trust. The Trust and its affiliate, the LLC, are consolidated with Alcor as Alcor has control of the Trust. Alcor's Board of Directors appoints the Trust's board members. All significant intercompany transactions have been eliminated in consolidation.

Alcor's operations include performing research and development for the cryopreservation or biostasis process, maintaining current patients in biostasis, placing members into biostasis, eventually restoring all patients to health if it becomes possible, and providing public education.

The Endowment Trust, which was formed in 2013, holds and utilizes significant resources that must be used exclusively for the purposes of Alcor. Accordingly, Alcor has an economic interest in the Endowment Trust. Additionally, Alcor has control over the Endowment Trust through a shared board of directors.

The Trust is an irrevocable trust that maintains amounts funded for patients in biostasis. The Trust pays Alcor for itemized expenses related to patient care. The Trust also owns the LLC.

The LLC owns the Alcor building and leases space to other tenants in addition to Alcor.

**Basis of presentation** – The consolidated financial statements are presented in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 958-205, *Not-for-Profit Entities* – *Presentation of Financial Statements*. Under FASB ASC 958-205, Alcor is required to report information regarding their financial position and activities according to three classes of net assets: unrestricted net assets, temporarily restricted net assets.

**Prior year summarized information** – The consolidated financial statements include certain prior year summarized comparative information in total but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with Alcor's consolidated financial statements for the year ended December 31, 2014, from which the summarized information was derived.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

#### (1) Nature of operations and summary of significant accounting policies (continued)

**Management's use of estimates** – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Estimates related to the deferred patient care reserve are particularly sensitive due to the nature of the estimate being highly sensitive to changes outside of management's control and the uncertainty surrounding future developments in the cryopreservation process, which relate specifically to patient maintenance and potential revival.

**Cash and cash equivalents** – Cash includes cash and, at times, cash equivalents, which consist of highly liquid financial investments purchased with an original maturity of three months or less. Accounts at each institution are insured in limited amounts by the Federal Deposit Insurance Corporation ("FDIC").

**Restricted cash** – Restricted cash is specifically reserved to provide standby services for Alcor's members. At December 31, 2015 and 2014, funds collected that had not been spent for their intended purpose are reported as restricted cash in the accompanying consolidated statement of financial position.

Accounts receivable – Accounts receivable consists primarily of amounts due for membership dues, CMS dues, and cryopreservations performed. Accounts receivable are stated at the amount management expects to collect. Management provides for uncollectible amounts through a charge to earnings and a credit to a valuation allowance based on its assessment of the current status of individual balances. Accounts receivable are considered impaired if full payments are not received in accordance with the contractual terms. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. At December 31, 2015 and 2014 accounts receivable are net of an allowance for doubtful accounts of \$99,000 and \$68,101, respectively.

**Property and equipment** – Property and equipment is recorded at cost. Donated property and equipment is recorded at its fair value at the date of gift to Alcor. Additions and betterments in excess of \$1,000 are capitalized. Maintenance and repairs that do not improve or extend the useful lives of the respective assets are expensed. Depreciation is computed using the straight-line method over the following general range of estimated useful lives:

Buildings and leasehold improvements 5 - 39 years
Machinery and office equipment 5 - 20 years
Medical equipment 5 - 20 years
Vehicles 5 years

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

#### (1) Nature of operations and summary of significant accounting policies (continued)

**Impairment of long-lived assets** – Alcor accounts for long-lived assets in accordance with the provisions of FASB ASC 360, *Property, Plant and Equipment*. FASB ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairment charges were recorded for the years ended 2015 and 2014.

**Investments** – Alcor accounts for its investments in accordance with FASB ASC 958-320, *Not-for-Profit Entities* – *Investments* – *Debt and Equity Securities* and FASB ASC 958-325, *Not-for-Profit Entities* – *Investments* – *Other.* Under FASB ASC 958-320, Alcor is required to report investments in equity securities that have readily determinable fair values, and all investments in debt securities, including negotiable certificates of deposit, at fair value. The fair value of securities with readily determinable fair values is based upon quoted market prices or publicly available net asset values. Negotiable certificates of deposit and U.S. Federal Agency securities are valued using proprietary valuation models incorporating live data from active market makers and inter-dealer brokers as reported on electronic communication networks. The valuation models incorporate benchmark yields, reported trades, broker/dealer quotes, bids, offers, and other data. Under FASB ASC 958-325, certificates of deposit investments that are not debt securities are stated at amortized cost, which approximates fair value.

In 2013, Alcor purchased an investment of preferred stock in a privately held company for which Alcor board members are officers. Under FASB ASC 958-325, Alcor accounts for the investment in this privately held company using the cost method. The total cost of the investment is \$190,000 as of December 31, 2015 and 2014.

Investments are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in risks in the near term could materially affect account balances and the amounts reported in the accompanying consolidated financial statements.

**Prepaid cryopreservation and standby** – Prepaid cryopreservation and standby services are refundable until services are provided and are recorded as a liability. Cryopreservation revenues and expenses are recognized upon the cryopreservation of a patient. Standby revenues and expenses are recognized upon providing emergency staff and transportation services to patients prior to cryopreservation, including all rescue activities up through the time the patient is transferred to the Alcor facilities for cryopreservation. At the time of providing these services, Alcor utilizes the assets held in prepaid cryopreservation and standby to fund the services.

Alcor is required to report prepaid cryopreservation and standby funds invested in equity securities that have readily determinable fair values and all investments in debt securities, at fair value. The fair value is based on quoted market prices. The certificates of deposit are valued at estimated fair market value based on the certificates' stated interest rate and current market interest rate. The life insurance policies are valued at the cash surrender value as of year-end as reported by the policy provider.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

#### (1) Nature of operations and summary of significant accounting policies (continued)

**Deferred patient care reserve** – Upon cryopreservation of a patient, a specified amount of the cryopreservation revenue is deferred and invested into the Alcor Patient Care Trust to be used for patient maintenance and potential revival. Upon potential revival, Alcor would recognize as revenue amounts held in the patient care trust reserved for the potentially revived patient. Costs to maintain the patient until such time that potential revival may be possible are expensed as incurred.

In 2014, the Board determined that the deferred patient care reserve should be increased due to expected future increases in the cost associated with companion animals. Consequently, in 2014 Alcor recognized an increase in the deferred patient care reserve and a loss of \$382,500 for this change in estimate.

The estimate for the deferred patient care reserve is developed using actuarial methods based on assumptions and estimates, and while management believes the amount is adequate, the ultimate liability may be in excess of or less than the amount deferred. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in each period when necessary.

**Membership dues** – Alcor does not provide significant tangible benefits to members for their membership in Alcor over the membership period. Accordingly, membership dues are recorded in accordance with contributions as described below.

**Contributions** – Alcor accounts for contributions in accordance with FASB ASC 958-605, *Not-for-Profit Entities* – *Revenue Recognition*. Contributions received are recorded as unrestricted, temporarily restricted, or permanently restricted support depending on the existence and/or nature of any donor restrictions. All donor-restricted support is reported as an increase in temporarily or permanently restricted net assets depending on the existence and/or nature of the restriction. When a restriction expires (that is, when a stipulated time restriction ends or purpose restriction is accomplished), temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities and changes in net assets as net assets released from restrictions. Restricted support, where restrictions are met in the same period as the donation is made, is shown as additions to unrestricted support.

**Bequests** – Bequests are recognized as contribution revenue in the period Alcor receives notification the court has found the will of the donor's estate to be valid and all conditions have been substantially met.

**Advertising** – Advertising costs are expensed as incurred, and amounted to \$1,455 and \$804 for the years ended December 31, 2015 and 2014, respectively.

**Functional expense allocation** – Expenses are charged to program services and supporting service categories based on direct expenditures incurred. Any expenditures not directly chargeable to a functional expense category are allocated based upon personnel activity or other appropriate indicators.

**Limited liability company** – Based on the type of organization of Cryonics Property, LLC (an indefinite life entity) and as otherwise provided in the operating agreement executed by the members of this company, no member is personally liable for any acts, debts or liabilities beyond the members' capital contributions.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

#### (1) Nature of operations and summary of significant accounting policies (continued)

**Fair value measurements** – FASB ASC 820, *Fair Value Measurements*, establishes a common definition for fair value to be applied to accounting principles generally accepted in the United States of America requiring use of fair value, establishes a framework for measuring fair value, and expands disclosures about such fair value measurements. FASB ASC 820 also establishes a hierarchy for ranking the quality and reliability of the information used to determine fair values by requiring that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

- Level 1: Unadjusted quoted market prices in active markets for identical assets or liabilities.
- Level 2: Unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability.
- Level 3: Unobservable inputs for the asset or liability.

**Income tax status** – Alcor, Alcor Endowment Trust Supporting Organization, and the Alcor Patient Care Trust qualify as tax-exempt organizations under Section 501(c)(3) of the Internal Revenue Code (the "Code") and, accordingly, there is no provision for income taxes. Alcor, Alcor Endowment Trust Supporting Organization and the Alcor Patient Care Trust are also exempt from state income tax. In addition, Alcor, Alcor Endowment Trust Supporting Organization and the Alcor Patient Care Trust qualify for the charitable contribution deduction under Section 170 of the Code and have been classified as organizations that are not private foundations. Income determined to be unrelated business taxable income ("UBTI") would be taxable.

Cryonics Property, LLC files its income tax return on the accrual basis as a partnership for federal and state income tax purposes. As such, Cryonics Property, LLC will not pay income taxes, as any income or loss will be included in the tax returns of the members.

Alcor, Alcor Endowment Trust Supporting Organization and the Alcor Patient Care Trust evaluate their uncertain tax positions, if any, on a continual basis through review of their policies and procedures, review of their regular tax filings, and discussions with outside experts.

Alcor's and Alcor Endowment Trust Supporting Organization's federal Return of Organization Exempt from Income Tax (Form 990) and the LLC's Form 1065 for 2015, 2014, and 2013 are subject to examination by the IRS, generally for three years after they were filed. The Alcor Patient Care Trust is included within Alcor's Form 990.

Recent accounting pronouncements – In May 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606) that will supersede most current revenue recognition guidance, including industry-specific guidance. The core principle of the new guidance is that an entity will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. Additionally, the guidance requires disclosures related to the nature, amount, timing, and uncertainty of revenue that is recognized.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

#### (1) Nature of operations and summary of significant accounting policies (continued)

In August 2015, the FASB issued FASB ASU No. 2015-14, *Revenue from Contracts with Customers (Topic 606)*, which changed the effective date of the provisions of FASB ASU No. 2014-09. As a result, the new effective dates for public business entities, certain not-for-profit entities, and certain employee benefit plans to apply the guidance in FASB ASU No. 2014-09 is for annual reporting periods beginning after December 15, 2017. All other entities should apply the guidance in FASB ASU No. 2014-09 to annual reporting periods beginning after December 15, 2018. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016. Transition to the new guidance may be done using either a full or modified retrospective method. Alcor is currently evaluating the full effect that the adoption of this standard will have on the consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). ASU 2016-02 requires that a lease liability and related right-of-use-asset representing the lessee's right to use or control the asset be recorded on the balance sheet upon the commencement of all leases except for short-term leases. Leases will be classified as either finance leases or operating leases, which are substantially similar to the classification criteria for distinguishing between capital leases and operating in existing lease accounting guidance. As a result, the effect of leases in the consolidated statement of activities and changes in net assets and the consolidated statement of cash flows will be substantially unchanged from the existing lease accounting guidance. The ASU is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. Alcor is currently evaluating the full effect that the adoption of this standard will have on the consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-14, *Not-for-Profit Entities (Topic 958), Presentation of Financial Statements of Not-for-Profit Entities*. ASU 2016-14 improves the current net asset classification requirements and the information presented in financial statements and notes about a not-for-profit entity's liquidity, financial performance, and cash flows. ASU 2016-14 is effective for annual financial statements issued for fiscal years beginning after December 15, 2017. Early application is permitted. The amendments of this ASU are to be applied on a retrospective basis in the year that the ASU is first applied. Alcor is currently evaluating the full effect that the adoption of this standard will have on the consolidated financial statements.

In November 2016, the FASB issued ASU 2016-18, *Restricted Cash*, requiring that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The amendments in ASU 2016-18 do not provide a definition of restricted cash or restricted cash equivalents. The guidance is effective for periods beginning after December 15, 2019, on a retrospective basis. Alcor is currently evaluating the full effect that the adoption of this standard will have on the consolidated financial statements.

In January 2016, the FASB issued ASU 2016-01, *Recognition and Measurement of Financial Assets and Financial Liabilities*, which provides guidance for the recognition, measurement, presentation, and disclosure of financial assets and liabilities. This ASU will be effective for us beginning in January 1, 2019 and requires modified-retrospective adoption. Alcor is evaluating the effects of our adoption of this ASU on our financial statements, as it relates to the equity investment held at cost.

**Subsequent events** – Alcor has evaluated subsequent events through May 17, 2018 which is the date the consolidated financial statements were available to be issued.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

### (2) Investments

Alcor's investments consists of the following at December 31:

	 2015	_	2014
Negotiable certificates of deposit (fair value)	\$ 5,089,951	\$	4,487,375
PIMCO enhanced short maturity exchange traded fund	352,839		1,859,504
Cash and cash equivalents	279,645		4,786,977
Index fund - DOW30	779,959		761,602
Index fund - S&P 500	784,035		759,980
Index fund - NASDAQ-100	778,115		735,524
Other exchange traded funds	277,514		323,688
Domestic large blend mutual funds	4,394,165		-
Certificates of deposit (amortized cost)	-		400,000
Other common stock and equity mutual funds	1,992,626		519,822
Unregistered preferred stock	190,000		190,000
Real estate investment trust	15,733		-
U.S. Federal agency securities	-		18,804
Money market funds	 15,892		6,123
Total investments	\$ 14,950,474	\$	14,849,399

### (3) Property and equipment

Property and equipment consists of the following at December 31:

	2015			2014	
Cost or donated value:					
Land, buildings, and leasehold improvements	\$	937,659	\$	904,422	
Machinery and office equipment		266,855		195,943	
Medical equipment		977,493		946,323	
Vehicles		74,260		74,260	
Total cost or donated value		2,256,267		2,120,948	
Accumulated depreciation		(1,543,592)		(1,443,755)	
Net property and equipment	\$	712,675	\$	677,193	

Depreciation expense charged to operations was \$103,961 and \$102,519 for the years ended December 31, 2015 and 2014, respectively.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

### (4) Beneficial interest in perpetual trust

Alcor is the sole beneficiary of an irrevocable trust that is held by a third party in perpetuity. Alcor records its interest in the trust assets at the fair value of the underlying assets of the trust. The beneficial interest in the trust is classified as permanently restricted. The unit of account for fair value measurement related to this beneficial interest is the beneficial interest itself, and not the underlying assets of the trust. There are no unadjusted quoted market prices in active markets for identical beneficial interests (Level 1 inputs) and no other observable inputs in active or inactive markets specific to beneficial interests (Level 2 inputs). Accordingly, the fair value of the beneficial interest is based upon unobservable inputs for the beneficial interest (Level 3 inputs). The fair value of Alcor's beneficial interest in the perpetual trust totaled \$3,509,058 and \$3,320,068 at December 31, 2015 and 2014, respectively.

The trust provides for an annual distribution of income and principal equal to the amount of 1% of the fair value of the trust as determined on the second calendar day of each calendar year. Distributions are recognized as investment income in the period of the distribution. Distribution income totaled \$33,200 and \$31,226 for the years ended December 31, 2015 and 2014, respectively.

The trust includes a provision that, upon the successful revival of the trustor from a cryopreserved state, the trustee shall distribute any part of the trust property not disposed by the provisions of the trust to the trustor. Resuscitation of members is not yet possible and, accordingly, Alcor has recognized its full interest in the perpetual trust as permanently restricted. If resuscitation becomes possible in the future, Alcor will reevaluate the accounting for this trust agreement under the provisions of FASB ASC 450, *Contingencies*.

### (5) Prepaid cryopreservation and standby

Alcor must maintain funds for prepaid cryopreservation and standby services in separate accounts for each member, per the cryopreservation contracts. As of January 1, 2001, Alcor instituted a policy requiring new members to name Alcor as the beneficiary of any life insurance policy the member uses to fund their cryopreservation. Policies can be returned to members at any time.

The following is a summary of those investments and life insurance policies at December 31:

	 2015	2014
Cash	\$ 3,586,112	\$ 2,064,342
Common stock	 248,621	 193,038
Total member investments	3,834,733	2,257,380
Cash surrender value of member life insurance policies	 4,649,497	 4,327,232
Total prepaid cryopreservation and standby	\$ 8,484,230	\$ 6,584,612

Alcor has a financial obligation to provide standby services to members residing in the continental U.S. and Canada. Standby services include emergency staff and transportation services to patients prior to cryopreservation, including all rescue activities necessary to bring the patient to the Alcor facilities for cryopreservation. Members pay cryopreservation and standby fees to Alcor to fund future standby expenses. Cryopreservation and standby fees will be recognized as revenue as standby expenses are incurred.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

#### (6) Deferred patient care reserve

Alcor has a financial obligation to fund the maintenance and potential revival of members who have undergone cryopreservation. The actual amount of future expenses required to meet this obligation is unknown due to the uncertainty of how long Alcor must maintain its members in cryopreservation and the uncertain costs of potential revival, if potential revival ever becomes scientifically and legally possible in the future. Therefore, these amounts are presently reflected as a deferred item. It is at least reasonably possible that this significant estimate will change in the near term.

#### (7) Functional expenses

Alcor conducts research and education in the field of cryopreservation and storage. Expenses related to providing these services are as follows:

		2015	 2014
Program	\$	1,479,595	\$ 1,228,639
General and administrative		520,219	373,495
Fundraising		40,730	16,384
Cryonics Property, LLC, net of eliminations		89,569	71,543
Total	<u>\$</u>	2,130,113	\$ 1,690,061

During the years ended December 31, 2015 and 2014, Alcor purchased \$88,520 and \$75,896 of services, respectively, from a company for which Alcor board members are officers.

#### (8) Line of credit

Alcor has a \$100,000 revolving line of credit agreement which was amended in November 2014 to remove the maturity date and change the terms of the line of credit such that is due upon 90 day notice from the lender. The line of credit is subject to interest at the prime rate plus 1.3% (4.8% and 4.25% at December 31, 2015 and 2014, respectively) within a minimum of 3% to be paid monthly. The line of credit is collateralized by future rights, title, interest and claims of Alcor, and substantially all property of Alcor. As of December 31, 2015 and 2014, no amounts were outstanding under this line of credit.

### (9) Leases and commitments

There are no material future minimum lease payments related to noncancelable operating leases with terms of one year or more at December 31, 2015. Rent expense totaled \$3,594 and \$3,516 for the years ended December 31, 2015 and 2014, respectively.

Cryonics Property, LLC is the lessor for office space under operating leases. The leases expire at various periods through December 2021. Rent income totaled \$26,031 and \$49,205 for the years ended December 31, 2015 and 2014, respectively.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

### (9) Leases and commitments (continued)

Future minimum lease payments expected to be received as of December 31, 2015 are as follows:

Years Ending December 31,		
2016	\$	65,242
2017		133,361
2018		120,827
2019		89,314
2020		91,980
Thereafter		94,716
Total future minimum payments	<u>\$</u>	595,440

Alcor has an agreement to pay royalty fees to a third party for the use of certain medical technologies. The fee is paid in annual installments due in September of each year, expiring in September 2020. The remaining commitments for this agreement as of December 31, 2015 are as follows:

Years Ending December 31,	
2016	\$ 21,630
2017	22,279
2018	22,947
2019	23,636
2020	 24,345
Total remaining commitments	\$ 114,837

#### (10) Retirement plan

Alcor has a 401(k) defined contribution plan (the "Plan") covering all employees meeting certain eligibility requirements. The Plan calls for contributions equal to 50% of the first 6% of eligible employee deferrals. Effective January 1, 2012, the Plan was amended to adopt a Safe Harbor non-elective contribution on behalf of each eligible employee in an amount equal to 3% of the eligible employee's compensation for the Plan year. Alcor contributed \$26,918 and \$25,812 to the Plan for the years ended December 31, 2015 and 2014, respectively.

### (11) Contingencies

Alcor is subject to various claims, legal proceedings, and investigations covering a wide range of matters that may arise in the ordinary course of business. Management believes the resolution of claims and pending litigation will not have a material effect on Alcor's consolidated results of operations.

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

#### (12) Fair value measurements

The following table sets forth the level, within the fair value hierarchy of Alcor's assets and liabilities subject to recurring fair value measurement as of December 31, 2015:

	 Level 1	 Level 2	 Level 3
PIMCO enhanced short maturity ETF	\$ 352,839	\$ -	\$ -
Index fund-DOW30	779,959	-	-
Index fund-NASDAQ-100	778,115	-	-
Index fund-S&P 500	784,035	-	-
Other exchange traded funds	277,514	-	-
Other common stocks and equity mutual funds	2,241,247	-	-
Negotiable certificates of deposit	-	5,089,951	-
Real estate investment trust	15,733	-	-
Money market funds	15,892	-	-
Domestic large blend mutual funds	4,394,165	-	-
Beneficial interest in perpetual trust	 -	-	 3,509,058
Total	\$ 9,639,499	\$ 5,089,951	\$ 3,509,058

The following table sets forth the level, within the fair value hierarchy of Alcor's assets and liabilities subject to recurring fair value measurement as of December 31, 2014:

	Level 1		_	Level 2	Level 3		
PIMCO enhanced short maturity ETF	\$	1,859,504	\$	-	\$	-	
Index fund-DOW30		761,602		-		-	
Index fund-NASDAQ-100		735,524		-		-	
Index fund-S&P 500		759,980		-		-	
Other exchange traded funds		323,688		-		-	
Other common stocks and equity mutual funds		712,860		-		-	
Negotiable certificates of deposit		-		4,487,375		-	
Money market funds		6,123		-		-	
U.S. Federal agency securities		-		18,804		-	
Beneficial interest in perpetual trust						3,320,068	
Total	<u>\$</u>	5,159,281	\$	4,506,179	\$	3,320,068	

Alcor had no other assets or liabilities subject to fair value measurements other than at initial recognition.

The table below presents the changes in fair value measurements that used level 3 inputs during the year ended December 31, 2015:

	i	Beneficial interest in perpetual trust		
Balance at January 1, 2015	\$	3,320,068		
Change in value of beneficial interest in perpetual trust		188,990		
Balance at December 31, 2015	<u>\$</u>	3,509,058		

#### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Year Ended December 31, 2015 (with comparative totals for the year ended December 31, 2014)

### (12) Fair value measurements (continued)

The table below presents the changes in fair value measurements that used level 3 inputs during the year ended December 31, 2014:

	i	interest in perpetual trust		
Balance at January 1, 2014	\$	3,122,530		
Change in value of beneficial interest in perpetual trust Balance at December 31, 2014	\$	197,538 3,320,068		

The fair value of the beneficial interest agreement is recorded at the fair value of the investment which is held by a third-party trustee and then adjusted for Alcor's interest in the assets. The fair value of the beneficial interest is estimated to approximate the fair value of the underlying assets of the trust itself. While the underlying assets of the trust are primarily observable, the value of beneficial interest itself is not observable in markets and, accordingly, this trust is classified within Level 3 of the valuation hierarchy.



#### INDEPENDENT ACCOUNTANTS' REVIEW REPORT ON SUPPLEMENTAL INFORMATION

Our report on our review of the basic consolidated financial statements of *Alcor Life Extension Foundation, Inc. and Affiliates* as of and for the year ended December 31, 2015, appears on page 1. The objective of our review was to perform procedures to obtain limited assurance as a basis for reporting whether we were aware of any material modifications that should be made to the consolidated financial statements for them to be in accordance with accounting principles generally accepted in the United States of America. The supplemental information included in the accompanying schedule of departmental assets, liabilities, and net assets and schedule of departmental revenue and expenses that follows on pages 18 and 19 is presented for purposes of additional analysis and is not a required part of the basic consolidated financial statements. Such information is the responsibility of management and was derived from, and relates to, the underlying accounting and other records used to prepare the consolidated financial statements. The supplementary information has been subjected to the review procedures applied in our review of the basic consolidated financial statements. We are not aware of any material modifications that should be made to the supplementary information. We have not audited the supplemental information and do not express an opinion on such information.

Mayer Hoffman McCam P.C.
May 17, 2018

### **SUPPLEMENTAL INFORMATION**

December 31, 2015

### SCHEDULE OF DEPARTMENTAL ASSETS, LIABILITIES AND NET ASSETS

<u>ASSETS</u>										
	Alcor	Patient Care Trust	Cryonics Property, LLC	Endowment Trust	Consolidating and Eliminating	Total				
CURRENT ASSETS  Cash and cash equivalents	\$ 1,031,886		\$ 149,585	\$ -	\$ -	\$ 1,392,475				
Accounts receivable, net	182,780 159,010	211,414	- 35,946	-	(319,540)	74,654				
Other current assets	159,010	<u>-</u>	35,946			194,956				
TOTAL CURRENT ASSETS	1,373,676	422,418	185,531	-	(319,540)	1,662,085				
RESTRICTED CASH	514,979	-	-	-	-	514,979				
PROPERTY AND EQUIPMENT, net	222,320	462,296	28,059	-	-	712,675				
INVESTMENTS	1,124,651	9,431,658	-	4,394,165	-	14,950,474				
BENEFICIAL INTEREST IN PERPETUAL TRUST	1,754,529	1,754,529	-	-	-	3,509,058				
PREPAID CRYOPRESERVATION AND STANDBY	8,484,230					8,484,230				
TOTAL ASSETS	\$ 13,474,385	\$ 12,070,901	\$ 213,590	\$ 4,394,165	\$ (319,540)	\$ 29,833,501				
CURRENT LIABILITIES Accounts payable Accrued expenses	\$ 466,265 35,505	* - -	\$ 8,100 15,124	\$ - -	\$ (319,540)	\$ 154,825 50,629				
TOTAL CURRENT LIABILITIES	501,770	-	23,224	-	(319,540)	205,454				
DEFERRED CRYOPRESERVATION AND STANDBY REVENUE	8,484,230	-	-	-	-	8,484,230				
DEFERRED COMPREHENSIVE MEMBER STANDBY REVENUE	527,520	-	-	-	-	527,520				
DEFERRED REVENUE	133,616	-	8,503	-	-	142,119				
DEFERRED PATIENT CARE RESERVE		8,135,000				8,135,000				
TOTAL LIABILITIES	9,647,136	8,135,000	31,727		(319,540)	17,494,323				
NET ASSETS Unrestricted										
Controlling interest Noncontrolling interest	2,072,720	2,181,372	181,863	4,394,165 	(40,541) 40,541	8,789,579 40,541				
Total unrestricted	2,072,720	2,181,372	181,863	4,394,165	-	8,830,120				
Temporarily restricted Permanently restricted	1,754,529	1,754,529				3,509,058				
TOTAL NET ASSETS	3,827,249	3,935,901	181,863	4,394,165		12,339,178				
TOTAL LIABILITIES AND NET ASSETS	\$ 13,474,385	\$ 12,070,901	\$ 213,590	\$ 4,394,165	\$ (319,540)	\$ 29,833,501				

### **SUPPLEMENTAL INFORMATION**

Year Ended December 31, 2015

### SCHEDULE OF DEPARTMENTAL REVENUES AND EXPENSES

		Alcor		Patient Care Trust		Cryonics operty, LLC	Er	ndowment Trust		nsolidating and liminating		Total
REVENUE AND SUPPORT												
Membership dues	\$	434,862	\$	_	\$	_	\$	_	\$	_	\$	434,862
Bequests	Ψ	279,488	Ψ	_	Ψ	_	Ψ	_	Ψ	_	Ψ	279,488
Contributions		414,659		_		_		_		(68,192)		346,467
Interest and distribution income		67,887		152,278		81		66,843		(2,466)		284,623
interest and distribution modifie		07,007		102,270		01		00,040		(2,400)		204,020
Realized and unrealized losses on investments		(90,551)		(319,321)		-		(232,066)		-		(641,938)
Cryopreservation and standby		776,136		-		-		-		-		776,136
Rental income		-		-		113,171		-		(87,140)		26,031
Change in value of beneficial interest in						-,				(- , - ,		-,
perpetual trust		94,495		94,495		-		-		-		188,990
Other		48,554		-		-		-		-		48,554
TOTAL REVENUE AND SUPPORT		2,025,530		(72,548)		113,252		(165,223)		(157,798)		1,743,213
		2,020,000		(12,0.0)	_	,202	-	(.00,220)		(101,100)		.,,
EXPENSES												
Payroll and benefits		606,376		47,685		-		-		-		654.061
Professional fees		93,836		14,322		14,866		4,200		-		127,224
Marketing		22,849		-		-		-,		_		22,849
Depreciation		38,057		39,308		26,596		-		-		103,961
Bad debts		93,812		-		-		-		-		93,812
Office supplies		50,620		9,989		107		-		-		60,716
Cryopreservation		358,181		210		750		-		-		359,141
Liquid nitrogen		-		29,779		-		-		-		29,779
Utilities		37,814		9,310		2,558		-		-		49,682
Insurance		54,208		4,053		2,352		-		-		60.613
Taxes, licenses and permits		641		16,520		26,510		-		-		43,671
Readiness		78,554		8,538		-		-		-		87,092
Royalty		20,268		· -		-		-		-		20,268
Contract services		2,400		-		12,633		-		-		15,033
Repairs and maintenance		11,505		3,365		4,796		-		(2,466)		17,200
Bank charges		32,663		7,191		19		-		-		39,873
Travel		5,429		· -		848		-		-		6,277
Research and development		60,454		-		-		-		-		60,454
Lease expense		3,257		337		-		-		-		3,594
Public education		274,683		130		-		-		-		274,813
Miscellaneous		-		-		-		68,192		(68,192)		-
Occupancy		59,662		27,478		-		-		(87,140)		-
TOTAL EXPENSES		1,905,269		218,215		92,035		72,392		(157,798)		2,130,113
CHANGE IN NET ASSETS		120,261		(290,763)		21,217		(237,615)				(386,900)
NET ASSETS, BEGINNING OF YEAR		3,706,988		4,226,664		160,646		4,631,780		<u>-</u>		12,726,078
NET ASSETS, END OF YEAR	\$	3,827,249	\$	3,935,901	\$	181,863	\$	4,394,165	\$		\$	12,339,178